For everyone paying cash for GLP-1s while technically holding insurance, fall open enrollment is the one window each year when the coverage question reopens. Most people sleepwalk through it and re-check the same box. Here's how to actually work the window.
Key Takeaways
- Open enrollment (roughly Nov 1–Jan 15 for ACA marketplace plans; employer windows vary, typically Oct–Nov) is when you can switch to a plan that covers weight-management GLP-1s.
- The document that matters is each candidate plan's 2027 formulary — search it for the specific drugs, and note the tier and prior-authorization flags.
- Run the real math: premium delta + deductible + copay tier vs. 12 months of 2026 cash-pay pricing. Cash sometimes wins.
- Coverage decisions made now take effect January 1 — this is genuinely a use-it-or-wait-a-year window.
Step 1: Get the 2027 Formularies
Every plan you're considering publishes a formulary — the covered-drug list — for the coming year. Find the 2027 document (not the current one; coverage changes annually) and search it for the specific brand names: Wegovy, Zepbound, Ozempic, Rybelsus. For each hit, note three things: whether the weight-management indication is covered (some plans cover a molecule for diabetes only), which cost tier it sits on, and whether prior authorization (PA) or step therapy is flagged.
Step 2: Decode PA and Step Therapy
PA means your prescriber must document you meet criteria — usually BMI thresholds, comorbidities, and sometimes prior participation in a lifestyle program. Step therapy means trying specified alternatives first. Neither is a "no"; both are paperwork with a timeline. If two plans cover the drug and one has no PA, that difference is worth real money in friction alone.
Step 3: Run the Honest Math
The comparison is annual, not monthly:
| Scenario | What you pay | Notes |
|---|---|---|
| Plan covering brand GLP-1, tier 3 + PA | Premium delta + deductible + ~$60–$150/mo copay | Brand-name product; PA renewal annually |
| Current plan, cash-pay compounded | $0 premium change + $49–$199/mo at 2026 prices | No PA; compounded (not FDA-approved) |
| Current plan, cash-pay brand via manufacturer programs | Varies; direct-purchase brand programs have expanded in 2026 | Brand product without insurance — check current manufacturer pricing |
At 2026's compounded prices, cash-pay legitimately beats a plan whose premium jumps hundreds monthly for the coverage. At brand tier-2 with a modest premium delta, insurance wins. There's no universal answer — only your arithmetic.
Step 4: If You Choose the Coverage Path
Line up the PA ingredients now: documented BMI history, comorbidity records, and a prescriber willing to file. PAs approved in January come from paperwork gathered in November.
And If Cash-Pay Keeps Winning
Then open enrollment's job is simply not to overpay for coverage you won't use — and the cash market is where your leverage lives:
Telos Rx — Semaglutide
Compounded semaglutide — from $49/mo on 12-month plans
Flat-at-every-dose semaglutide with commitment-tier pricing and FSA/HSA acceptance.
Compounded medications are not FDA-approved.
Visit Telos Rx Paid linkGala
Injectable — $179/mo flat, every dose
Flat pricing at every dose — one of the simplest billing models in GLP-1 telehealth.
Compounded medications are not FDA-approved.
Visit Gala Paid linkWellorithm
Oral tablets — sema $147/mo, tirz $249/mo
Lowest published oral compounded pricing we track, tablets for both molecules.
Compounded medications are not FDA-approved.
Visit Wellorithm Paid linkOne hour with two formularies and a calculator, once a year. It's the highest-hourly-rate financial work most GLP-1 patients will ever do.
Affiliate disclosure: Links marked "Paid link" are affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. This supports our independent research.
Compounded medication notice: Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Brand-name alternatives (Wegovy, Ozempic, Zepbound, Rybelsus) are FDA-approved.
Medical disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs. Always consult a licensed healthcare provider about diagnosis, treatment, dosing, and whether these medications are appropriate for you.